A familiar form, backed by serious hormone care.
Prescription oral estradiol puts established hormone therapy into a familiar, straightforward daily form.
About 10 minutes. No charge unless your clinician approves.
The simplest format still deserves nuance.
Estradiol is the estrogen at the center of menopause medicine. As levels decline through perimenopause and menopause, hot flashes, night sweats, disrupted sleep, and vaginal dryness can become part of daily life.
The tablet is the least complicated way to deliver it.
One dose, once a day, swallowed with a routine you already know how to keep. For many women that familiarity is a real advantage. No patch placement, no gel drying time, no new technique to learn.
The clinical tradeoff is route. Oral estradiol passes through the liver before reaching circulation, which gives it a different risk profile from transdermal therapy. That does not make the tablet the wrong format. It makes route selection an actual medical decision rather than a lifestyle preference dressed up as one.
The tablet is a familiar, straightforward form of systemic estrogen therapy. Its simplicity is a practical strength, while the oral route carries specific risks that deserve direct discussion before prescribing.
Read the evidence →For women who want hormone therapy to fit the routine they already have.
The Routine Keeper
You already take a morning or evening medication and know exactly where a tablet belongs. The easiest new habit may be the one that does not feel new at all.
Menopause Is Affecting the Week
Hot flashes, night sweats, and sleep disruption are no longer abstract symptoms on a checklist. Estrogen therapy is the most effective treatment medicine has for moderate to severe vasomotor symptoms, and your provider determines whether it fits your risk profile.
The Skin Route Is Not Appealing
Adhesives irritate some skin. Gel adds an application step. For some women, the cleanest practical answer is simply oral therapy, provided the clinical risk conversation supports it.
Route selection here is individualized, never a default. A licensed provider weighs oral estradiol against your history and risk profile from your Assessment. Compounded by a licensed 503A pharmacy and not an FDA-approved drug product.
This might not be the right fit if:
- History of breast cancer or another estrogen-dependent malignancy
- Unexplained vaginal bleeding
- History of blood clots, stroke, or heart attack
- Active liver disease
- Pregnancy or planned pregnancy
Your intake screens for all contraindications. Every candidate is evaluated by a licensed clinician before any prescription is issued. No prescription is issued without clearance.
Estradiol Tablet, prescribed with care.
Compounded by a licensed 503A pharmacy. Prescribed by a licensed provider after clinical review.
- Bioidentical 17-beta estradiol in a once-daily oral tablet
- Taken on the schedule directed by your provider
- Dose selected and adjusted from symptoms, response, and clinical history
- Paired with micronized progesterone when you have a uterus, per standard of care
- Ongoing provider review with route changes available when clinically appropriate
Prescription issued subject to provider judgment. Results vary. Not a guarantee of outcomes.
*Price reflects a 3 month commitment. Other billing options are shown at checkout.
More in Hormones & Vitality.
Estradiol Gel
Menopause symptoms should not set the pace.
Prescription estradiol gel delivers systemic estrogen through the skin in an adjustable daily format.
Estradiol Patches
Twice weekly. Steady by design.
Prescription estradiol patches provide steady transdermal delivery with a twice-weekly change schedule.
Estradiol Vaginal Cream
Local treatment for an intimate problem.
Prescription vaginal estradiol delivers local treatment directly to the tissue at the center of the concern.
What the research shows
Pooled oral hormone therapy cut weekly hot flushes by 75 percent relative to placebo.
The detail
A Cochrane review of oral hormone therapy for hot flushes pooled 24 double-blind, randomized, placebo-controlled trials lasting three months to three years, with 3,329 participants. Weekly hot flush frequency fell by a weighted mean of 17.92 episodes more than placebo, 95 percent confidence interval 12.99 to 22.86, equivalent to a 75 percent reduction relative to placebo, 95 percent confidence interval 64.3 to 82.3. Symptom severity also fell, odds ratio 0.13, 0.07 to 0.23, and withdrawal for lack of efficacy was far more common on placebo, odds ratio 10.51, 5.00 to 22.09.1
Oral estradiol cut hot flashes by 16.8 more per week than placebo.
The detail
A systematic review of 32 randomized, double-blind, placebo-controlled trials of estrogen for menopausal hot flashes, 14 of which met criteria for meta-analysis, pooled five trials of oral 17-beta estradiol to a weighted mean difference of 16.8 fewer hot flashes per week than placebo, 95 percent confidence interval 10.2 to 23.4, and six trials of transdermal 17-beta estradiol to 22.4 fewer per week, 10.4 to 35.9. The differences between agents were not statistically significant.2
On estrogen alone endometrial hyperplasia was common; with a progestin it matched placebo.
The detail
The reason a progestogen belongs in the plan was measured directly. In the Postmenopausal Estrogen/Progestin Interventions trial, a 3-year multicenter randomized, double-masked, placebo-controlled trial in 596 postmenopausal women aged 45 to 64, women assigned to oral estrogen alone developed simple hyperplasia in 27.7 percent of cases, complex hyperplasia in 22.7 percent and atypical hyperplasia in 11.8 percent, against 0.8 percent, 0.8 percent and 0 percent on placebo, p less than 0.001. All three estrogen plus progestin regimens had hyperplasia rates statistically indistinguishable from placebo, p equals 0.16.3
The two WHI trials of oral therapy did not find the same thing.
The detail
The Women’s Health Initiative ran two separate randomized, double-blind, placebo-controlled trials of oral therapy, and they did not find the same thing. In 16,608 postmenopausal women aged 50 to 79 with a uterus given oral conjugated equine estrogens 0.625 mg plus medroxyprogesterone acetate 2.5 mg, hazard ratios over a mean 5.2 years were 1.29 for coronary heart disease, 95 percent confidence interval 1.02 to 1.63, 1.26 for invasive breast cancer, 1.00 to 1.59, 1.41 for stroke, 1.07 to 1.85, and 2.13 for pulmonary embolism, 1.39 to 3.25.4 In 10,739 women with a prior hysterectomy given conjugated equine estrogens alone for an average 6.8 years, stroke rose, hazard ratio 1.39, 1.10 to 1.77, hip fracture fell, 0.61, 0.41 to 0.91, coronary heart disease was unchanged, 0.91, 0.75 to 1.12, and breast cancer was 0.77, 0.59 to 1.01.5 A prespecified analysis of both trials found the coronary result varied with time since menopause, hazard ratio 0.76 at under 10 years, 1.10 at 10 to 19 years and 1.28 at 20 or more years, p for trend 0.02, with stroke elevated regardless of timing.6
Oral hormone therapy carried a higher clot risk; transdermal did not.
The detail
The oral route has been compared with the transdermal route for clot risk, observationally. In two nested case-control studies covering 80,396 UK women aged 40 to 79 with a first venous thromboembolism between 1998 and 2017 and 391,494 matched controls, oral hormone therapy carried an adjusted odds ratio of 1.58 for venous thromboembolism, 95 percent confidence interval 1.52 to 1.64, 1.40 for estrogen-only oral preparations and 1.73 for combined; oral estradiol carried a lower risk than conjugated equine estrogen, 0.85, 0.76 to 0.95; and transdermal preparations were not associated with increased risk, 0.93, 0.87 to 1.01.7
What it does not show
No approved or established use for anti-aging, cognitive protection or cardiovascular prevention.
The detail
The approved uses are specific, and none of them is longevity. Oral estradiol tablet labeling covers moderate to severe vasomotor symptoms due to menopause, moderate to severe symptoms of vulvar and vaginal atrophy, hypoestrogenism due to hypogonadism, castration or primary ovarian failure, palliation in metastatic breast cancer and in advanced androgen-dependent prostate carcinoma, and prevention of osteoporosis. The boxed warning on that labeling states that estrogens with or without progestins should not be used for the prevention of cardiovascular disease. Nothing here is approved or established for anti-aging, cognitive protection or cardiovascular prevention.8
Placebo alone cut hot flushes by 57.7 percent.
The detail
Placebo did a great deal of the work. In the same Cochrane review, women randomized to placebo recorded a 57.7 percent reduction in hot flushes between baseline and end of study, 95 percent confidence interval 45.1 to 67.7, which is why the reviewers concluded that any therapy claiming to reduce these symptoms has to be tested blinded against placebo. Feeling better in the first weeks is not by itself evidence that the tablet is what changed.1
The tablet label still carries the older boxed warning as of August 2026.
The detail
The estradiol tablet labeling has not been revised yet, and the revision elsewhere is a reassessment rather than a disproof. On November 10, 2025 the FDA asked manufacturers of menopausal hormone therapy to remove the cardiovascular disease, breast cancer and probable dementia language from the boxed warning while retaining the endometrial cancer boxed warning for systemic estrogen-alone products, and approved the first revised labels on February 12, 2026. As of August 2026 no estradiol tablet label posted on DailyMed has been revised; the approved oral labeling still carries the older generic-format boxed warning headed by endometrial cancer risk, with a cardiovascular and other risks section describing the Women’s Health Initiative results.8910
No trial cited here tested a compounded tablet.
The detail
Two limits on how far these results reach. The clot comparison between routes is a case-control analysis of prescribing records, not a randomized comparison, so it cannot establish that the route is the cause. And the Women’s Health Initiative tested oral conjugated equine estrogens rather than oral 17-beta estradiol; the labeling states that in the absence of comparable data the risks should be assumed to be similar, which is an assumption rather than a measurement. No trial cited here tested a compounded tablet.4578
- MacLennan AH, Broadbent JL, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus… Cochrane Database Syst Rev. 2004;(4):CD002978.
- Nelson HD. Commonly used types of postmenopausal estrogen for treatment of hot… JAMA. 2004.
- The Writing Group for the PEPI Trial Effects of hormone replacement… JAMA. 1996.
- Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal… JAMA. 2002.
- Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with… JAMA. 2004.
- Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by… JAMA. 2007.
- Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of venous thromboembolism… BMJ. 2019.
- FDA-approved prescribing information, Estradiol Tablets, USP, Teva Pharmaceuticals USA Inc, label version 16 published February 2024.DailyMed
- US Food and Drug Administration. FDA requests labeling changes related to safety information to clarify… Drug safety statement, November 10, 2025.FDA
- US Food and Drug Administration. FDA approves labeling changes to menopausal hormone therapy products. Press announcement, February 12, 2026.FDA
Approved estradiol labeling carries a boxed warning that estrogen without a progestogen increases the risk of endometrial cancer in a woman who still has a uterus, so unopposed systemic estrogen is not an appropriate plan in that situation and progesterone belongs in the conversation from the start.
Do not use if you have
- A history of breast cancer or another estrogen-dependent cancer
- Unexplained vaginal bleeding
- A prior blood clot, stroke or heart attack
- An inherited clotting disorder
- Liver disease
- A known hypersensitivity to the ingredients of the tablet
- Pregnancy
Serious risks
- Stroke, deep vein thrombosis and pulmonary embolism
- Gallbladder disease
- Probable dementia in women who begin therapy at 65 or older
- Breast cancer when estrogen and a progestogen are taken together over longer use
Commonly reported
- Headache
- Breast tenderness
- Nausea
- Bloating
- Irregular vaginal bleeding or spotting
Because it is a tablet
- Swallowed estradiol passes through the liver before it reaches circulation, which is one reason route is a clinical decision rather than a preference you select
Your provider weighs your age, your history, and how long you have been postmenopausal before prescribing, and revisits that judgment as your care continues. The serious risks are estrogen class risks, and they are the reason this is prescribed rather than sold.
Asked and answered.
You are not charged, and you are not left guessing. Your clinician explains the reasoning and, where it helps, what a better path might look like. Reviews are typically completed in under 24 hours.
Systemic estrogen therapy carries risks including blood clots and stroke, and oral estrogen in particular is associated with a higher clot risk than transdermal routes for some women. Combined therapy has also been associated with increased breast cancer risk over longer use. Your provider reviews your personal risk before prescribing and discusses it with you plainly, not in fine print.
If you have a uterus, yes: systemic estrogen without a progestogen raises the risk of endometrial overgrowth and cancer, so micronized progesterone is paired alongside as standard of care. If you have had a hysterectomy, estradiol is typically prescribed on its own. Your provider makes that call from your history.
Yes. You can cancel at any time, and your plan is never locked to a format. If the tablet is not fitting your life or your body, message your care team: your provider can adjust the dose or move you to a gel or patch when clinically appropriate. Nothing here runs on inertia.